Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
This study evaluates the interest of regorafenib in combination of metronomic chemotherapies and low-dose aspirin as a 2 months induction therapy before chemotherapy initiation in the second-line metastatic colorectal carcinoma
Metastatic Colorectal Cancer
OTHER: quality of life questionnaires|PROCEDURE: Blood sample|DRUG: Regorafenib|DRUG: Metronomic chemotherapies|DRUG: Aspirin|DRUG: Bevacizumab|DRUG: FOLFIRI or FOLFOX
best objective response during treatment period (phase II), the best response rate evaluated with RECIST v1.1 criteria per an independent radiologist committee during the treatment period defined as the number of with complete response (CR) or partial response (PR) as best response divided by the total number of patients evaluable. Patients for whom best overall tumor response is not CR or PR will be considered non-responders., during treatment period (from first treatment administration and disease progression, an average of 14 months|overall survival (OS) (phase III), Overall survival is defined as the time from the randomization to death from any cause., through study completion, an average of 64 months
This study evaluates the interest of regorafenib in combination of metronomic chemotherapies and low-dose aspirin as a 2 months induction therapy before chemotherapy initiation in the second-line metastatic colorectal carcinoma